We know that healthy changes can be extremely difficult to make and maintain even when determined. Liver damage caused by alcohol can lead to changes in the body that you may not be aware of. For example, portal hypertension.
Portal hypertension is another way of saying that the pressure in the main blood vessel going to the liver is too high. And although you might not have any outward symptoms, clinically significant portal hypertension (CSPH) is responsible for most complications in people with alcohol-related liver cirrhosis e.g. ascites (collection of fluid in the stomach) and varices (abnormal enlargement of veins which could lead to rupturing and bleeding). Because of this, Boehringer Ingelheim are conducting the 1366-0021 clinical research trial to study the effect of an investigation medication on portal hypertension.
They are looking for people to join the study, who, among other things:
- Are between 18 and 75 years old (inclusive)
- Have been diagnosed with compensated alcohol-related liver cirrhosis
- Have not consumed significant amounts of alcohol in the last 2 months
If you’re interested in taking part or would like more information about the study, please contact your nearest study site below quoting ‘1366-0021 Boehringer study’:
PI Name: Dr Mark Wright
Site Address: GBR2, Southampton Centre for Biomedical Research, University Hospital Southampton NHS-FT, Southampton, SO16 6YD
Phone: 023 8120 4149
PI Name: Prof Dhiraj Tripathi
Site Address: GBR4, Robert Aitken Institute of Clinical Research, Research & Development (Liver), University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TH
PI Name: Prof Raj Mookerjee
Site Address: GBR3, National Institute for Health and Care Research (NIHR) Royal Free Clinical Research Facility (CRF), 2nd Floor, Royal Free Hospital, Pond Street, London, NW3 2QG
Phone: 020 7794 0500